Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase – Should You Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares saw an uptick in trading volume on Tuesday . 245,208 shares were traded during trading, an increase of 181% from the previous session’s volume of 87,171 shares.The stock last traded at $8.1040 and had previously closed at $8.05.

Trending Headlines about Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set a $20 price target on TLX, implying significant upside from current levels; this supports a constructive long‑term thesis. HC Wainwright Reaffirmation
• Neutral Sentiment: Company provided a Precision Medicine portfolio update (Illuccix China Phase 3, TLX101‑CDx and TLX250‑CDx FDA resubmissions) — progress on clinical and regulatory dossiers that is relevant to long‑term value but may take time to materialize. Portfolio Update
• Negative Sentiment: Multiple law firms have filed or publicized securities‑class action claims and investor notices covering the Feb. 21–Aug. 28, 2025 period, urging investors to act by early January — allegations cite an SEC subpoena and an FDA CRL related to CMC/supply‑chain/manufacturing deficiencies. These developments created heavy headline risk and were tied to a prior sharp share drop. Representative notices: Hagens Berman (SEC subpoena & FDA CRL) Hagens Berman Notice, Berger Montague notice Berger Montague, and a PR Newswire item noting a ~21% TLX plunge tied to these issues PR Newswire.
• Negative Sentiment: Additional plaintiff‑firm notices (Levi & Korsinsky, The Gross Law Firm, Bronstein Gewirtz, Faruqi & Faruqi, Portnoy, etc.) increase the likelihood of consolidated litigation and ongoing legal costs/distraction for management. Example: Levi & Korsinsky investor notice. Levi & Korsinsky

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Canaccord Genuity Group raised Telix Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 6th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Price Performance

The stock has a 50-day moving average price of $9.76 and a 200 day moving average price of $11.77.

Institutional Trading of Telix Pharmaceuticals

Large investors have recently bought and sold shares of the company. Rhumbline Advisers increased its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the last quarter. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter worth $213,000. Blair William & Co. IL bought a new position in Telix Pharmaceuticals during the 2nd quarter worth $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter valued at $297,000. Finally, JPMorgan Chase & Co. bought a new stake in Telix Pharmaceuticals in the third quarter valued at $243,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.